Reuters logo
BRIEF-Clovis Oncology says ‍Ariel3 study successfully achieved primary endpoint​
September 7, 2017 / 10:18 PM / 15 days ago

BRIEF-Clovis Oncology says ‍Ariel3 study successfully achieved primary endpoint​

Sept 7 (Reuters) - Clovis Oncology Inc

* Clovis oncology presents comprehensive dataset from successful phase 3 Ariel3 maintenance treatment trial of Rucaparib in advanced ovarian cancer at ESMO 2017

* Says ‍safety data from ariel3 demonstrate consistency with prior Rucaparib studies​

* Says ‍Ariel3 study successfully achieved its primary endpoint​

* Says ‍Rucaparib improved objective response rate versus. Placebo among evaluable trial participants in all three study populations​

* Says ‍Ariel3 study also successfully achieved key secondary endpoint​

* Says ‍Rucaparib improved objective response rate versus. Placebo among evaluable trial participants in all three study populations​

* Says ‍plans to submit snda to U.S. FDA for a second line or later maintenance treatment indication in ovarian cancer by end of October 2017​

* Says ‍in early 2018 plans to file MAA in Europe for maintenance treatment indication upon receipt of potential approval for treatment indication​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below